AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (6.3 MB)
Collect
AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Fire needling ameliorates chronic eczema-associated pruritus in mice: Concurrent downregulation of the CXCL10–CXCR3–MrgprA3–TRPV1 pathway

Yu AnaHao GebJing XucYajie LiudZhixiu LineBaixiao Zhaob( )
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China
School of Acupuncture-Moxibustion Tuina, Beijing University of Chinese Medicine, Beijing 102488, China
Department of Acupuncture, Shaanxi Provincial People’s Hospital, Xi’an 710068, China
Department of Acupuncture, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361015, China
School of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong SAR 999077, China

Peer review under responsibility of Beijing University of Chinese Medicine.

Show Author Information

Abstract

Objective

To investigate the effects of a digital electric fire-needling acupuncture device (EFNA) in a mouse model of chronic eczema (CE) and aimed to elucidate its underlying antipruritic mechanisms.

Methods

Forty bagg albino (BALB)/c mice were randomly assigned to 4 groups: control, model, EFNA, and halometasone groups (n = 10). Except for the control group, CE was induced in all groups using 2,4-dinitrochlorobenzene. After model establishment, mice in the EFNA group received EFNA treatment at the lesional skin sites, whereas the halometasone group received a dose-tapering regimen of topical halometasone for two weeks. The eczema area severity index of the dorsal skin, and scratching frequency (bouts/10 min) were assessed after model induction and treatment. The splenic index was recorded post-intervention. Hematoxylin and eosin staining evaluated skin morphology, and Western blot analysis determined expression levels of CXC motif chemokine ligand 10 (CXCL10), CXC chemokine receptor type 3 (CXCR3), mas-related g-protein coupled receptor member A3 (MrgprA3), and transient receptor potential vanilloid 1 (TRPV1) in skin tissue.

Results

Both EFNA and halometasone markedly reduced eczema area severity index scores (both P < .001), significantly decreased scratching frequency (P = .010, P = .007), and reduced the spleen index (P = .029, P < .001). EFNA also alleviated edema and epidermal thickening in lesional skin, decreased local lymphocyte infiltration, and downregulated CXCL10, CXCR3, MrgprA3, and TRPV1 expression in skin tissues (all P < .001).

Conclusion

EFNA ameliorated 2,4-dinitrochlorobenzene-induced chronic eczematous lesions, with reductions in pruritus, inflammatory edema and cellular infiltration, alongside downregulation of CXCL10, CXCR3, MrgprA3, and TRPV1. These findings suggest that the antipruritic effect of EFNA may involve modulation of the non-histaminergic itch transmission pathway, providing new insights into the mechanism of fire-needling therapy for CE.

References

【1】
【1】
 
 
Journal of Traditional Chinese Medical Sciences
Pages 401-410

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
An Y, Ge H, Xu J, et al. Fire needling ameliorates chronic eczema-associated pruritus in mice: Concurrent downregulation of the CXCL10–CXCR3–MrgprA3–TRPV1 pathway. Journal of Traditional Chinese Medical Sciences, 2026, 13(3): 401-410. https://doi.org/10.1016/j.jtcms.2026.06.007

6

Views

0

Downloads

0

Crossref

0

Scopus

Received: 30 November 2025
Revised: 14 June 2026
Accepted: 14 June 2026
Published: 19 June 2026
© 2026 Beijing University of Chinese Medicine.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).